Fonteyne V - Search Results

1

ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer.

Salembier C, Villeirs G, De Bari B, Hoskin P, Pieters BR, Van Vulpen M, Khoo V, Henry A, Bossi A, De Meerleer G, Fonteyne V. Salembier C, et al. Among authors: fonteyne v. Radiother Oncol. 2018 Apr;127(1):49-61. doi: 10.1016/j.radonc.2018.01.014. Radiother Oncol. 2018. PMID: 29496279

2

Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.

Verghote F, Van Praet C, Berquin C, Lumen N, Decaestecker K, Vanneste B, Rammant E, Fonteyne V. Verghote F, et al. Among authors: fonteyne v. BMC Cancer. 2024 Jan 31;24(1):160. doi: 10.1186/s12885-024-11927-1. BMC Cancer. 2024. PMID: 38297192 Free PMC article.

3

Is It Safe to Switch from a Standard Anterior to Retzius-Sparing Approach in Robot-Assisted Radical Prostatectomy?

Lambert E, Allaeys C, Berquin C, De Visschere P, Verbeke S, Vanneste B, Fonteyne V, Van Praet C, Lumen N. Lambert E, et al. Among authors: fonteyne v. Curr Oncol. 2023 Mar 17;30(3):3447-3460. doi: 10.3390/curroncol30030261. Curr Oncol. 2023. PMID: 36975474 Free PMC article.

4

The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review.

Rammant E, Fox L, Beyer K, Aaronson NK, Chaloner R, De Padova S, Liedberg F, Wintner LM, Decaestecker K, Fonteyne V, Perdek N, Wylie H, Catto JWF, Ripping TM, Holzner B, Van Leeuwen M, Van Hemelrijck M; EORTC Quality of Life Group. Rammant E, et al. Among authors: fonteyne v. Qual Life Res. 2023 Aug;32(8):2127-2135. doi: 10.1007/s11136-022-03335-4. Epub 2023 Jan 17. Qual Life Res. 2023. PMID: 36648569 Review.

5

Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity.

Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V, Arcangeli G, De Neve W, Storme G. Soete G, et al. Among authors: fonteyne v. Radiother Oncol. 2006 Jul;80(1):78-81. doi: 10.1016/j.radonc.2006.06.005. Epub 2006 Jul 7. Radiother Oncol. 2006. PMID: 16828910 Clinical Trial.

6

Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control.

De Meerleer GO, Fonteyne VH, Vakaet L, Villeirs GM, Denoyette L, Verbaeys A, Lummen N, De Neve WJ. De Meerleer GO, et al. Radiother Oncol. 2007 Feb;82(2):160-6. doi: 10.1016/j.radonc.2006.12.007. Epub 2007 Jan 12. Radiother Oncol. 2007. PMID: 17222931

7

Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.

Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G. Fonteyne V, et al. Radiother Oncol. 2007 Aug;84(2):156-63. doi: 10.1016/j.radonc.2007.06.013. Epub 2007 Aug 10. Radiother Oncol. 2007. PMID: 17692976

8

Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.

Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G. Fonteyne V, et al. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):799-807. doi: 10.1016/j.ijrobp.2008.01.040. Epub 2008 Apr 11. Int J Radiat Oncol Biol Phys. 2008. PMID: 18407430

9

Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.

Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G. Arcangeli S, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):39-45. doi: 10.1016/j.ijrobp.2008.04.005. Epub 2008 Jun 4. Int J Radiat Oncol Biol Phys. 2009. PMID: 18538488 Clinical Trial.

10

Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.

De Meerleer G, Fonteyne V, Meersschout S, Van den Broecke C, Villeirs G, Lumen N, Ost P, Vandecasteele K, De Neve W. De Meerleer G, et al. Among authors: fonteyne v. Radiother Oncol. 2008 Nov;89(2):205-13. doi: 10.1016/j.radonc.2008.07.027. Epub 2008 Sep 2. Radiother Oncol. 2008. PMID: 18771809

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters